EyePoint Pharmaceuticals, Inc.
(NASDAQ : PSDV)

( )
PSDV After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
0.42%35.790.8%$770.07m
JNJJohnson & Johnson
-0.46%123.670.6%$760.71m
ABBVAbbVie, Inc.
0.20%106.192.1%$722.36m
MRKMerck & Co., Inc.
-0.96%58.570.6%$604.58m
BMYBristol-Myers Squibb Company
-0.85%52.261.4%$500.81m
LLYEli Lilly and Company
-0.31%81.821.0%$359.74m
AZNAstraZeneca PLC Sponsored ADR
1.27%36.791.3%$155.36m
NVSNovartis AG Sponsored ADR
-0.38%76.770.2%$134.45m
GSKGlaxoSmithKline plc Sponsored ADR
0.04%40.050.2%$111.29m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.05%48.700.1%$80.32m
SNYSanofi Sponsored ADR
-0.26%38.780.2%$45.06m
LCILannett Company, Inc.
5.73%17.0837.9%$12.98m
EPIXESSA Pharma Inc
-7.04%3.300.0%$0.19m
AKTXAkari Therapeutics Plc Sponsored ADR
-7.37%1.761.7%$0.11m

Company Profile

EyePoint Pharmaceuticals, Inc. develops tiny, sustained-release products, which are designed to deliver drugs and biologics at a controlled and steady rate for weeks, months or years. The company through its technology platforms Duraser and Tethadur is focused on treatment of chronic diseases of the back of the eye and are also exploring applications outside ophthalmology. It is also developing a bioerodible, injectable micro-insert delivering latanoprost to treat glaucoma and ocular hypertension. The company was founded by Roger Aston in March 2008 and is headquartered in Watertown, MA.